Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers in this study are assessing the drug ACR-368 alone and in combination with increasing doses of low-dose gemcitabine in people with ovarian, endometrial, or urothelial (bladder) cancer that has come back despite prior treatment. ACR-368 works by stopping cancer cells from repairing damage to themselves and their DNA (genes). Gemcitabine damages the DNA inside cancer cells and prevents the cells from multiplying.
Researchers want to see if  dietary changes can affect chemotherapy response or quality of life in people newly diagnosed with multiple myeloma. The people in this study are receiving standard induction (initial) chemotherapy with daratumumab or isatuximab, lenalidomide, bortezomib, and dexamethasone (DRVd).
Researchers want to find the best dose of iberdomide that can be given with elranatamab in people with multiple myeloma. The people in this study have multiple myeloma that came back or keeps growing even after treatment.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
ARV-393 targets and breaks down a protein called BCL6. This protein is found in cancer cells and plays a role in their growth and survival. By breaking down BCL6, ARV-393 may help slow or stop the growth of your cancer. It is taken orally (by mouth).
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers want to find the best doses of BNT324 and BNT327 when given together to treat lung cancer. The people in this study have lung cancer that spread and came back or got worse after treatment.
Researchers are doing this study is to find the highest dose of a new cell therapy for people with leukemia. The people in this study have acute myelogenous leukemia (AML) that keeps growing even after treatment. They will get the new treatment with atezolizumab, an immune-boosting therapy.
Cells that are "mismatch repair-deficient" (MMR-D) or "microsatellite instability-high" (MSI-H) are unable to repair mistakes made during cell growth. Women with MMR-D/MSI-H endometrial cancer tend not to respond well to the chemotherapy they receive after surgery. Researchers are exploring the use of the immunotherapy TSR-042 (also called dostarlimab) as an alternative to chemotherapy. Radiation therapy is also used after surgery for endometrial cancer.
